Growth hormone secretagogue
Ipamorelin
Early human researchA selective ghrelin-receptor agonist that stimulates growth hormone release.
Evidence
Early human research
Regulatory status
Not FDA-approved.
Class
Growth hormone secretagogue
What it is
Ipamorelin acts on the ghrelin receptor (GHS-R) to trigger growth hormone release. It was developed to be more selective than earlier compounds in its class.
What the research shows
- Early research described its selectivity for growth hormone release in animal models.
- It was studied in human trials for post-operative ileus (slowed gut function after surgery) but was not approved.
Read the published research on PubMed →
Researched for
Ipamorelin is not FDA-approved for the uses people commonly discuss. Its safety and effectiveness in people have not been established. Talk to a licensed provider before making any decision.
Educational content, not medical advice. This page does not recommend or dose any substance.
Related peptides
GHRH analog
Tesamorelin
A growth-hormone-releasing hormone analog with a narrow FDA approval.
FDA-approved drugGHRH analogSermorelin
A short GHRH fragment with a long research history.
Human clinical trialsLong-acting GHRH analogCJC-1295
A modified GHRH analog engineered to last longer in the body.
Early human research